The Bodewell line of OTC monograph skin care treatments for eczema and psoriasis returns to US stores five months after Procter & Gamble acquired the brand through its P&G Ventures early-stage startup studio.
Bodewell OTC Eczema, Psoriasis Treatments Relaunched After P&G Ventures’ Acquisition
The line, using colloidal oatmeal for eczema, salicylic acid for psoriasis or pyrithione zinc for flaky scalp, was independently launched in beta by a Vancouver, BC, start-up in January 2020 and debuted in May that year.
More from Retail
• By
Almost two thirds (62%) of respondents to an online survey said they would rather buy non-prescription medicines in a local pharmacy than via a mail-order pharmacy, Pharma Deutschland reports.
• By
Retailer JC Penney Company, Inc.’s use of Revieve Inc.’s virtual try-on and beauty advisor tools has driven significant increases in online engagement, average order rates and conversion rates for makeup, skin and hair care versus the retailer’s other e-commerce products.
• By
Although FDA concluded OTC oral phenylephrine is ineffective as a nasal decongestant in doses up to highest studied level, federal preemption precludes challenges to agency’s regulation of labeling for phenylephrine and other Rx and OTC drugs, according to recent decision in New York federal court.
• By
Firm’s future, as a separate business nearly 90% owned by Bausch Health, or as a standalone with different ownership or one not controlled by a majority owner, claims high profile in analysts’ comments and predictions. B+L is in the driver’s seat, they say.
More from Business
• By
Alliance shareholders overwhelmingly back takeover by DBAY Advisors after improved offer values UK-based firm at £362m.
• By
Like many European firms, Stada Arzneimittel's 2024 earnings were held back by a soft cough, cold and flu season. However, key launches in its home market Germany and in the Middle East offset this impact and led to 3% organic growth for Stada's Consumer Healthcare business.
• By
Key growth driver in consumer health and across Bayer’s sectors, says CEO Bill Anderson, is “dynamic shared ownership program” introduced in January 2024 to "reduce hierarchies, eliminate bureaucracy, streamline structures and accelerate decision-making processes."